A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
JCO Oncol Pract
; 18(9): e1533-e1541, 2022 09.
Article
em En
| MEDLINE
| ID: mdl-35724357
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Octreotida
/
Tumores Neuroendócrinos
Tipo de estudo:
Clinical_trials
/
Guideline
/
Prognostic_studies
/
Qualitative_research
Idioma:
En
Revista:
JCO Oncol Pract
Ano de publicação:
2022
Tipo de documento:
Article